These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 31402238)

  • 1. Long term follow up of persistence of immunity following quadrivalent Human Papillomavirus (HPV) vaccine in immunocompromised children.
    MacIntyre CR; Shaw PJ; Mackie FE; Boros C; Marshall H; Seale H; Kennedy SE; Moa A; Chughtai AA; Trent M; O'Loughlin EV; Stormon M
    Vaccine; 2019 Sep; 37(37):5630-5636. PubMed ID: 31402238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity and persistence of immunity of a quadrivalent Human Papillomavirus (HPV) vaccine in immunocompromised children.
    MacIntyre CR; Shaw P; Mackie FE; Boros C; Marshall H; Barnes M; Seale H; Kennedy SE; Moa A; Hayen A; Chughtai AA; O'Loughlin EV; Stormon M
    Vaccine; 2016 Aug; 34(36):4343-50. PubMed ID: 27406936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation on the persistence of anti-HPV immune responses to the quadrivalent HPV vaccine in Chinese females and males: Up to 3.5 years of follow-up.
    Huang T; Liu Y; Li Y; Liao Y; Shou Q; Zheng M; Liao X; Li R
    Vaccine; 2018 Mar; 36(11):1368-1374. PubMed ID: 29428178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity and reactogenicity of alternative schedules of HPV vaccine in Vietnam: a cluster randomized noninferiority trial.
    Neuzil KM; Canh DG; Thiem VD; Janmohamed A; Huong VM; Tang Y; Diep NT; Tsu V; LaMontagne DS
    JAMA; 2011 Apr; 305(14):1424-31. PubMed ID: 21486975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy, immunogenicity, and safety of a quadrivalent HPV vaccine in men: results of an open-label, long-term extension of a randomised, placebo-controlled, phase 3 trial.
    Goldstone SE; Giuliano AR; Palefsky JM; Lazcano-Ponce E; Penny ME; Cabello RE; Moreira ED; Baraldi E; Jessen H; Ferenczy A; Kurman R; Ronnett BM; Stoler MH; Bautista O; Das R; Group T; Luxembourg A; Zhou HJ; Saah A
    Lancet Infect Dis; 2022 Mar; 22(3):413-425. PubMed ID: 34780705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sustainability of neutralising antibodies induced by bivalent or quadrivalent HPV vaccines and correlation with efficacy: a combined follow-up analysis of data from two randomised, double-blind, multicentre, phase 3 trials.
    Mariz FC; Gray P; Bender N; Eriksson T; Kann H; Apter D; Paavonen J; Pajunen E; Prager KM; Sehr P; Surcel HM; Waterboer T; Müller M; Pawlita M; Lehtinen M
    Lancet Infect Dis; 2021 Oct; 21(10):1458-1468. PubMed ID: 34081923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity of the 9-Valent HPV Vaccine Using 2-Dose Regimens in Girls and Boys vs a 3-Dose Regimen in Women.
    Iversen OE; Miranda MJ; Ulied A; Soerdal T; Lazarus E; Chokephaibulkit K; Block SL; Skrivanek A; Nur Azurah AG; Fong SM; Dvorak V; Kim KH; Cestero RM; Berkovitch M; Ceyhan M; Ellison MC; Ritter MA; Yuan SS; DiNubile MJ; Saah AJ; Luxembourg A
    JAMA; 2016 Dec; 316(22):2411-2421. PubMed ID: 27893068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term immunogenicity, effectiveness, and safety of nine-valent human papillomavirus vaccine in girls and boys 9 to 15 years of age: Interim analysis after 8 years of follow-up.
    Olsson SE; Restrepo JA; Reina JC; Pitisuttithum P; Ulied A; Varman M; Van Damme P; Moreira ED; Ferris D; Block S; Bautista O; Gallagher N; McCauley J; Luxembourg A
    Papillomavirus Res; 2020 Dec; 10():100203. PubMed ID: 32659510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of safety and immunogenicity of a quadrivalent human papillomavirus vaccine in healthy females between 9 and 26 years of age in Sub-Saharan Africa.
    Mugo N; Ansah NA; Marino D; Saah A; Garner EI
    Hum Vaccin Immunother; 2015; 11(6):1323-30. PubMed ID: 25912475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity of 2 and 3 Doses of the Quadrivalent Human Papillomavirus Vaccine up to 120 Months Postvaccination: Follow-up of a Randomized Clinical Trial.
    Donken R; Dobson SRM; Marty KD; Cook D; Sauvageau C; Gilca V; Dionne M; McNeil S; Krajden M; Money D; Kellner J; Scheifele DW; Kollmann T; Bettinger JA; Liu S; Singer J; Naus M; Sadarangani M; Ogilvie GS
    Clin Infect Dis; 2020 Aug; 71(4):1022-1029. PubMed ID: 31617568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A ten-year study of immunogenicity and safety of the AS04-HPV-16/18 vaccine in adolescent girls aged 10-14 years.
    Schwarz TF; Huang LM; Valencia A; Panzer F; Chiu CH; Decreux A; Poncelet S; Karkada N; Folschweiller N; Lin L; Dubin G; Struyf F
    Hum Vaccin Immunother; 2019; 15(7-8):1970-1979. PubMed ID: 31268383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9-14 years: Results to month 12 from a randomized trial.
    Leung TF; Liu AP; Lim FS; Thollot F; Oh HM; Lee BW; Rombo L; Tan NC; Rouzier R; Friel D; De Muynck B; De Simoni S; Suryakiran P; Hezareh M; Folschweiller N; Thomas F; Struyf F
    Hum Vaccin Immunother; 2015; 11(7):1689-702. PubMed ID: 26062002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of HPV 16 and HPV 18 antibody responses by pseudovirus neutralization, Merck cLIA and Merck total IgG LIA immunoassays in a reduced dosage quadrivalent HPV vaccine trial.
    Krajden M; Cook D; Yu A; Chow R; Su Q; Mei W; McNeil S; Money D; Dionne M; Palefsky J; Karunakaran K; Kollmann T; Ogilvie G; Petric M; Dobson S
    Vaccine; 2014 Jan; 32(5):624-30. PubMed ID: 24055350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and tolerability to human papillomavirus-like particle vaccine in girls and young women with inflammatory bowel disease.
    Jacobson DL; Bousvaros A; Ashworth L; Carey R; Shrier LA; Burchett SK; Renna H; Lu Y
    Inflamm Bowel Dis; 2013 Jun; 19(7):1441-9. PubMed ID: 23567780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and safety of two novel human papillomavirus 4- and 9-valent vaccines in Chinese women aged 20-45 years: A randomized, blinded, controlled with Gardasil (type 6/11/16/18), phase III non-inferiority clinical trial.
    Shu Y; Yu Y; Ji Y; Zhang L; Li Y; Qin H; Huang Z; Ou Z; Huang M; Shen Q; Li Z; Hu M; Li C; Zhang G; Zhang J
    Vaccine; 2022 Nov; 40(48):6947-6955. PubMed ID: 36283897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial.
    Dobson SR; McNeil S; Dionne M; Dawar M; Ogilvie G; Krajden M; Sauvageau C; Scheifele DW; Kollmann TR; Halperin SA; Langley JM; Bettinger JA; Singer J; Money D; Miller D; Naus M; Marra F; Young E
    JAMA; 2013 May; 309(17):1793-802. PubMed ID: 23632723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in HIV-1-infected women.
    Kojic EM; Kang M; Cespedes MS; Umbleja T; Godfrey C; Allen RT; Firnhaber C; Grinsztejn B; Palefsky JM; Webster-Cyriaque JY; Saah A; Aberg JA; Cu-Uvin S
    Clin Infect Dis; 2014 Jul; 59(1):127-35. PubMed ID: 24723284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity of a 9-valent HPV vaccine in females 12-26 years of age who previously received the quadrivalent HPV vaccine.
    Garland SM; Cheung TH; McNeill S; Petersen LK; Romaguera J; Vazquez-Narvaez J; Bautista O; Shields C; Vuocolo S; Luxembourg A
    Vaccine; 2015 Nov; 33(48):6855-64. PubMed ID: 26411885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sustained Antibody Responses 6 Years Following 1, 2, or 3 Doses of Quadrivalent Human Papillomavirus (HPV) Vaccine in Adolescent Fijian Girls, and Subsequent Responses to a Single Dose of Bivalent HPV Vaccine: A Prospective Cohort Study.
    Toh ZQ; Russell FM; Reyburn R; Fong J; Tuivaga E; Ratu T; Nguyen CD; Devi R; Kama M; Matanitobua S; Tabrizi SN; Garland SM; Sinha R; Frazer I; Tikoduadua L; Kado J; Rafai E; Mulholland EK; Licciardi PV
    Clin Infect Dis; 2017 Apr; 64(7):852-859. PubMed ID: 28034886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in Chinese females aged 9 to 26 years: A phase 3, open-label, immunobridging study.
    Huang Z; He J; Su J; Ou Z; Liu G; Fu R; Shou Q; Zheng M; Group T; Luxembourg A; Liao X; Zhang J
    Vaccine; 2021 Jan; 39(4):760-766. PubMed ID: 33239228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.